Mark Leong – Executive Chairman – Osteopore (ASX:OSX) is a Singapore-headquartered corporation poised to be a leading medical device company in the region. It is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery use.
Copyright 2023 – Finance News Network
Source: Finance News Network
03 Sep 2020 - Hazer Group (ASX:HZR) CEO & Managing Director, Geoff Ward talks about FY20 achievements, its final investment decision for its Commercial Development Plant to process low emissions hydrogen gas and high purity graphite production from biogas, development and commercial programs.
Read More10 Feb 2021 - Centuria Capital Group Limited (ASX:CNI) Joint CEO, John McBain talks 1H21 results & outlook, transactions and financial highlights.
Read More13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
Read More29 Jul 2022 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent key announcements, including the appointment of a US sales team, the securing of a US patent, quarterly results, and the year ahead.
Read More22 May 2020 - Novonix Limited (ASX:NVX) Managing Director Philip St Baker talks about the company's breakthrough dry particle microgranulation (DPMG) method for reducing waste in the manufacture of anode and cathode materials for lithium-ion batteries, restarting of operations in North America and outlook for 2H20.
Read More24 Oct 2019 - BluGlass Limited (ASX:BLG) Managing Director and CEO, Giles Bourne, discusses the launch of the company's new laser diode business and how this fits into its strategy.
Read More16 Dec 2019 - Openpay Group (ASX:OPY) CEO & MD, Michael Eidel talks about its business model, size of the opportunity and how it differentiates itself from other buy now pay later (BNPL) providers.
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More20 Nov 2023 - ABX Group (ASX:ABX) Managing Director Mark Cooksey speaks about rare earth resources, advancing sustainable aluminum production with promising growth for investors in the coming months.
Read More03 Mar 2020 - Catapult Limited (ASX:CAT) CEO, Will Lopes discusses 1H20 results and outlook.
Read More
